Two things. I understand Dr Garner is on record as saying he’s...

Two things. I understand Dr Garner is on record as saying he’s looking for this to be a billion dollar company. So if he gets an offer for something close to that, presumably he’ll take it. That puts some kind of cap on the value I guess.

Secondly, our drug appears to outperform any monotherapy, but the median PFS is not as good as the best combination therapy out there. So GDC-0084 doesn’t automatically become standard of care. It looks like we’ll need to try combination therapies to have any chance of becoming standard of care. So let’s not get too far ahead of ourselves.

nonetheless, at current prices, def a Buy in my view.